Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
ADPT - Adaptive Biotechnologies Corpor
Market Cap 1.15B P/E - EPS this Y 21.80% Ern Qtrly Grth -
Income -213.47M Forward P/E -7.88 EPS next Y 15.60% 50D Avg Chg 8.00%
Sales 168.77M PEG -0.19 EPS past 5Y - 200D Avg Chg -
Dividend N/A Price/Book 2.91 EPS next 5Y 21.60% 52W High Chg -40.00%
Recommedations 2.00 Quick Ratio 3.73 Shares Outstanding 147.47M 52W Low Chg 34.00%
Insider Own 1.92% ROA -17.18% Shares Float 76.82M Beta 1.43
Inst Own 98.42% ROE -67.01% Shares Shorted/Prior 9.63M/9.66M Price 7.96
Gross Margin -16.86% Profit Margin -126.49% Avg. Volume 1,029,233 Target Price 7.00
Oper. Margin -92.88% Earnings Date Nov 7 Volume 845,935 Change -3.52%
Healthcare | Biotechnology | United States
About Adaptive Biotechnologies Corpor

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

Adaptive Biotechnologies Corpor News
12/16/24 Are Medical Stocks Lagging BellRing Brands (BRBR) This Year?
12/09/24 Adaptive unveils data of MRD assessment test in blood cancer treatment
12/07/24 Adaptive Biotechnologies Announces New Data at the 66th ASH Annual Meeting Highlighting Advances in MRD Testing with clonoSEQ® and Its Impact on Blood Cancer Treatment Decisions
12/05/24 Adaptive Research and WRO to expand cancer trial access in San Francisco Bay Area
12/03/24 Adaptive Biotechnologies Announces Over 65 Abstracts Featuring clonoSEQ® MRD Testing Across a Range of Blood Cancers to be Presented at the 66th ASH Annual Meeting
11/29/24 Is Adaptive Biotechnologies (ADPT) Outperforming Other Medical Stocks This Year?
11/25/24 Novotech report notes shift to adaptive designs in clinical trials
11/15/24 Wall Street Analysts Predict a 31.36% Upside in Adaptive Biotechnologies (ADPT): Here's What You Should Know
11/13/24 Is Cardinal Health (CAH) Outperforming Other Medical Stocks This Year?
11/09/24 Adaptive Biotechnologies Third Quarter 2024 Earnings: Beats Expectations
11/08/24 Q3 2024 Adaptive Biotechnologies Corp Earnings Call
11/08/24 Adaptive Biotechnologies Corp (ADPT) Q3 2024 Earnings Call Highlights: Strong MRD Growth Amidst ...
11/07/24 Adaptive Biotechnologies (ADPT) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
11/07/24 Adaptive Biotechnologies (ADPT) Reports Q3 Loss, Tops Revenue Estimates
11/07/24 Adaptive Biotechnologies: Q3 Earnings Snapshot
11/07/24 Adaptive Biotechnologies Reports Third Quarter 2024 Financial Results
11/07/24 Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ® for Assessing Measurable Residual Disease in Mantle Cell Lymphoma
11/01/24 November 2024's Top US Penny Stocks With Growth Potential
10/09/24 Adaptive Biotechnologies to Report Third Quarter 2024 Financial Results on November 7, 2024
10/07/24 Is Teva Pharmaceutical Industries (TEVA) Stock Outpacing Its Medical Peers This Year?
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
PETERSON TYCHO Chief Financial Offi.. Chief Financial Officer Jun 20 Sell 8.14 134,961 1,098,583 399,219 06/21/23
PETERSON TYCHO Chief Financial Offi.. Chief Financial Officer Jun 20 Option 7.3 134,961 985,215 534,180 06/21/23
PETERSON TYCHO Chief Financial Offi.. Chief Financial Officer Jun 15 Sell 8.53 70,000 597,100 399,219 06/20/23
PETERSON TYCHO Chief Financial Offi.. Chief Financial Officer Jun 15 Option 7.3 14,328 104,594 413,547 06/20/23
ADAMS R MARK Chief Operating Offi.. Chief Operating Officer Apr 10 Sell 8.57 3,125 26,781 175,361 04/12/23
GRIFFIN MICHELLE RENEE Director Director Mar 27 Sell 8.4913 2,341 19,878 20,627 03/29/23
PISKEL KYLE Principal Accounting.. Principal Accounting Officer Mar 06 Sell 8.58 3,529 30,279 87,564 03/08/23
LO FRANCIS Chief People Officer Chief People Officer Mar 06 Sell 8.57 6,816 58,413 168,469 03/08/23
Taylor Stacy L SVP and General Coun.. SVP and General Counsel Mar 06 Sell 8.59 18,878 162,162 139,678 03/08/23
ADAMS R MARK Chief Operating Offi.. Chief Operating Officer Mar 06 Sell 8.59 23,684 203,446 178,486 03/08/23
BENZENO SHARON Chief Commercial Ofc.. Chief Commercial Ofc Imm Med Mar 06 Sell 8.57 11,749 100,689 223,826 03/08/23
SOOD NITIN Chief Commercial Off.. Chief Commercial Officer, MRD Mar 06 Sell 8.59 16,474 141,512 231,010 03/08/23
RUBINSTEIN JULIE President President Mar 06 Sell 8.57 22,668 194,265 336,824 03/08/23
ADAMS R MARK Chief Operating Offi.. Chief Operating Officer Jan 09 Sell 8.54 3,125 26,687 113,518 01/11/23
PISKEL KYLE Principal Accounting.. Principal Accounting Officer Nov 16 Sell 8.87 959 8,506 46,706 11/17/22
SOOD NITIN Chief Commercial Off.. Chief Commercial Officer, MRD Nov 01 Sell 8.00 31,066 248,528 114,505 11/01/22
SOOD NITIN Chief Commercial Off.. Chief Commercial Officer, MRD Aug 05 Sell 10.98 17,540 192,589 145,571 08/05/22
ADAMS R MARK Chief Operating Offi.. Chief Operating Officer Jul 07 Sell 10 3,125 31,250 119,768 07/08/22
ADAMS R MARK Chief Operating Offi.. Chief Operating Officer Apr 07 Sell 13.17 831 10,944 122,893 04/08/22
Taylor Stacy L SVP and General Coun.. SVP and General Counsel Mar 08 Sell 11.44 2,387 27,307 72,859 03/10/22
BALDO LANCE Chief Medical Office.. Chief Medical Officer Mar 08 Sell 11.43 3,350 38,290 17,171 03/10/22
LO FRANCIS Chief People Officer Chief People Officer Mar 08 Sell 11.44 3,582 40,978 89,588 03/10/22
ROBINS CHAD M CEO and Chairman CEO and Chairman Mar 07 Option 6.32 44,445 280,892 1,930,969 03/09/22
ROBINS CHAD M CEO and Chairman CEO and Chairman Mar 07 Sell 11.9 44,445 528,896 1,916,154 03/09/22
BALDO LANCE Chief Medical Office.. Chief Medical Officer Mar 07 Sell 12.01 2,373 28,500 20,521 03/08/22
RUBINSTEIN JULIE President President Mar 04 Sell 12.01 4,613 55,402 226,513 03/08/22
BENZENO SHARON Chief Business Devel.. Chief Business Development Off Mar 04 Sell 12.01 2,670 32,067 102,596 03/08/22
Taylor Stacy L SVP and General Coun.. SVP and General Counsel Mar 04 Sell 12.01 1,569 18,844 75,246 03/08/22
PISKEL KYLE Principal Accounting.. Principal Accounting Officer Mar 04 Sell 12.01 220 2,642 47,665 03/08/22
LO FRANCIS Chief People Officer Chief People Officer Mar 04 Sell 12.01 1,569 18,844 93,170 03/08/22
ROBINS HARLAN S Chief Scientific Off.. Chief Scientific Officer Mar 04 Sell 12.01 4,517 54,249 311,960 03/08/22
ROBINS CHAD M CEO and Chairman CEO and Chairman Mar 04 Sell 12.01 4,424 53,132 1,916,154 03/08/22
ADAMS R MARK Chief Operating Offi.. Chief Operating Officer Mar 04 Sell 12.01 1,244 14,940 123,724 03/08/22
ADAMS R MARK Chief Operating Offi.. Chief Operating Officer Jan 07 Sell 23.32 1,021 23,810 50,833 01/10/22
Taylor Stacy L SVP and General Coun.. SVP and General Counsel Dec 22 Option 7.18 15,338 110,127 30,374 12/23/21
Taylor Stacy L SVP and General Coun.. SVP and General Counsel Dec 22 Sell 30 15,338 460,140 15,036 12/23/21
Cohen Chad M Chief Financial Offi.. Chief Financial Officer Dec 22 Sell 30 10,000 300,000 21,604 12/23/21
Cohen Chad M Chief Financial Offi.. Chief Financial Officer Dec 22 Option 7.27 10,000 72,700 31,604 12/23/21
ROBINS HARLAN S Chief Scientific Off.. Chief Scientific Officer Oct 19 Option 6.55 11,200 73,360 73,060 10/21/21
ROBINS HARLAN S Chief Scientific Off.. Chief Scientific Officer Oct 19 Sell 33.53 11,200 375,536 69,360 10/21/21
ADAMS R MARK Chief Operating Offi.. Chief Operating Officer Oct 07 Sell 33.07 3,125 103,344 51,854 10/08/21
ROBINS HARLAN S Chief Scientific Off.. Chief Scientific Officer Oct 06 Option 6.32 11,685 73,849 73,255 10/08/21
ROBINS HARLAN S Chief Scientific Off.. Chief Scientific Officer Oct 06 Sell 32.85 11,685 383,852 69,360 10/08/21
ROBINS HARLAN S Chief Scientific Off.. Chief Scientific Officer Sep 15 Sell 37.15 11,685 434,098 69,360 09/15/21
ROBINS HARLAN S Chief Scientific Off.. Chief Scientific Officer Sep 15 Option 6.32 11,685 73,849 73,255 09/15/21
ROBINS CHAD M CEO and Chairman CEO and Chairman Sep 10 Sell 38.67 43,499 1,682,106 1,673,461 09/10/21
Cohen Chad M Chief Financial Offi.. Chief Financial Officer Sep 09 Sell 39.36 14,375 565,800 21,604 09/09/21
Cohen Chad M Chief Financial Offi.. Chief Financial Officer Sep 09 Option 6.91 14,375 99,331 26,604 09/09/21
Taylor Stacy L SVP and General Coun.. SVP and General Counsel Sep 09 Sell 40 495 19,800 15,036 09/09/21
Taylor Stacy L SVP and General Coun.. SVP and General Counsel Sep 09 Option 6.55 495 3,242 15,531 09/09/21